All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Metabolically engineered probiotic nanovaccine shows sequential immunomodulation for chronic MRSA bone infection treatment

This article presents research on developing a metabolically engineered nanovaccine using Lactococcus lactis outer membrane vesicles (Lac-OMVs) for treating chronic, drug-resistant bone infections caused by MRSA. The researchers screened Lac-OMVs and developed NAD+-Lac-OMV nanovaccines that sequentially modulate the immune system — first activating dendritic cells to fight infection, then reprogramming inflammatory macrophages to promote anti-inflammation and bone repair. The approach addresses the challenge of an immunosuppressive niche that enables persistent infection and impaired bone healing in chronic osteomyelitis.

Lei Tan Send email to [email protected]5d ago56 min readenInsight
Read on cell.com

Key quotes

Chronic, drug-resistant bone infection caused by methicillin-resistant Staphylococcus aureus (MRSA) features an immunosuppressive niche enabling persistent infection and impaired bone healing.
A specific treatment requires initial antibacterial immune activation against infection, followed by reshaping an anti-inflammatory microenvironment for later bone repair.
Lei et al. screen Lactococcus lactis OMVs (Lac-OMVs) and develop a metabolically engineered NAD+-Lac-OMV nanovaccine with potent tissue-repair therapeutic effects.
NAD+-Lac-OMVs sequentially activate dendritic cells by membrane components and reprogram inflammatory macrophages for anti-inflammation and bone repair by interior nicotinamide metabolites.

From the article

Lei et al. screen Lactococcus lactis OMVs (Lac-OMVs) and develop a metabolically engineered NAD+-Lac-OMV nanovaccine with potent tissue-repair therapeutic effects. NAD+-Lac-OMVs sequentially activate dendritic cells by membrane components and reprogram in
Continue reading on cell.com

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.